Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy

AIDS

Volumn 27, Issue 4, 2013, Pages 553-561

  Etiebet, Mary Ann A ^a   Shepherd, James ^a   Nowak, Rebecca G ^a   Charurat, Man ^a   Chang, Harry ^a   Ajayi, Samuel ^c   Elegba, Olufunmilayo ^d   Ndembi, Nicaise ^b   Abimiku, Alashle ^a   Carr, Jean K ^a   Eyzaguirre, Lindsay M ^a   Blattner, William A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF HUMAN VIROLOGY NIGERIA   (Nigeria)

^c UNIVERSITY OF ABUJA   (Nigeria)

^d NATIONAL HOSPITAL   (Nigeria)

Author keywords

drug resistance; HIV 1; non B subtype; resource limited settings; second line; tenofovir disoproxil fumarate; thymidine analog mutations

Indexed keywords

EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; TENOFOVIR; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; DRUG TREATMENT FAILURE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION; NIGERIA; PRIORITY JOURNAL; VIRUS LOAD;

ADENINE; ADULT; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MUTATION, MISSENSE; NIGERIA; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD; ZIDOVUDINE;

EID: 84873413113     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835b0f59     Document Type: Article

References (54)

1. http://www.pepfar.gov/about/138312.htm. Accessed November 23, 2010.
2. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first line antiretroviral therapy. AIDS 2009; 23:1127- 1134.
3. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for the second antiretroviral therapy regimen for HIV-infected patients whose initial regimen of fixed-dose combination of stavudine, lamivudine and nevirapine fails. Clin Infect Dis 2007; 44:447-452.
4. Kumarasamy N, Madhavan V, Venkatesh KK, Saravan S, Kantor R, Balakrishnan P, et al. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource limited settings. Clin Infect Dis 2009; 49:306-309.
5. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (2010 version). Geneva: WHO; 2010.
6. Miller MD. K65R, TAMS and tenofovir. AIDS Rev 2004; 6: 22-33.
7. Federal Ministry of Health N. HIV/Syphilis Sero-Prevalence and STD Syndromes Sentinel Survey among PTB and STD patients in Nigeria. Abuja: Federal Ministry of Health, Abuja; 2007.
8. McCutchan FE, Carr JK, Bajani M, Sanders-Buell E, Harry TO, Stoeckli TC, et al. Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria. Virology 1999; 254:226-234.
9. Abimiku AG, Stern TL, Zwandor A, Markham PD, Calef C, Kyari S, et al. Subgroup G HIV type 1 isolates from Nigeria. AIDS Res Hum Retroviruses 1994; 10:1581-1583.
10. Peeters M, Esu-Williams E, Vergne L, Montavon C, Mulanga- Kabeya C, Harry T, et al. Predominance of subtype A and GHIV type 1 in Nigeria, with geographical differences in their distribution. AIDS Res Hum Retroviruses 2000; 16:315-325.
11. FMOH/WHO. Situation of antiretroviral drug use in Nigeria. November 2003. Abuja: FMOH.
12. http://data.unaids.org/pub/Report/2010/nigeria-2010-country-progress- report-en.pdf. Accessed November 19, 2010.
13. Martínez-Cajas J, Pant-Pi N, Klein M, Wainberg M. Differences in resistance mutations among HIV-1 nonsubtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc 2009; 12:11.
14. Novitsky V, Wester W, Degruttola V, Bussman H, Gaseitsiwe S, Thomas A, et al. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in Southern Africa. AIDS Res Hum Retroviruses 2007; 23:868-878.
15. Chaplin B, Eisen G, Idoko J, Onwujekwe D, Idigbe E, Adewole I, et al. Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy. AIDS Res and Hum Retroviruses 2010; 26:1-9.
16. Munerato P, Sucupira MC, Oliveros M, Janini L, de Souza DF, Pereira A, et al. HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the city of Sao Paulo, Brazil. AIDS Res Hum Retroviruses 2010; 26:265-273.
17. Federal Ministry of Health. National guideline for HIV and AIDS care in adolescents and adults. 2nd ed. Abuja, Nigeria: FMOH, May 2007.
18. Eyzaguirre LM, Brouwer KC, Nadai Y, Patterson TL, Ramos R, Firestone Cruz M, et al. First molecular surveillance report of HIV type 1 in injecting drug users and female sex workers along the U.S.-Mexico border. AIDS Res Hum Retroviruses 2007; 23:331-334.
19. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980; 16:111-120.
20. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987; 4: 406-425.
21. Lole K, Bollinger R, Paranjape R, Gadkari D, Kulkarni S, Novak N, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999; 73:152- 160.
22. Boulme R, Gonzalez D, Schmit JC. Storing genotypic resistance data and linking to other clinical information. Poster presented at the XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004.
23. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011; 19:156-164.
24. Marcelin A, Delaugerre C, Wirden M, Viegas P, Simon A, Katlama C, et al. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 2004; 72:162-165.
25. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic resistance test interpretation. Clin Infect Dis 2006; 42:1608- 1618.
26. Kantor R, Katzenstein D, Efron B, Carvalho AP, Wynhoven B, Cane P, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2:e112.
27. Whitcomb JM, Parkin NT, Chappey C, Hellman NS, Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188:992-1000.
28. Brenner BG, Coutsinos D. The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. HIV Ther 2009; 3:583-594.
29. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002; 16:1227-1235.
30. Sunpath H, Wu B, Gordon M, Hampton J, Johnson B, Moosa M, et al. High rate of K65R for ART naive patients with subtype C HIV infection failing a TDF-containing first-line regimen in South Africa. AIDS 2012 [Epub ahead of print].
31. Hawkins CA, Chaplin B, Idoko J, Ekong E, Adewole I, Gashau W, et al. Clinical and genotypic findings in HIVinfected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr 2009; 52:228-234.
32. Coutsinos D, Invernizzi CF, Moisi D, Oliveira M, Martinez- Cajas JL, Brenner BG, Wainberg MA. A templatedependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. PLoS One 2011; 6:e20208; Epub 2011 May 31.
33. Gu Z, Fletcher RS, Arts EJ, Wainberg MA, Parnaik MA. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2′,3′- dideoxycytidine, 2′3′-dideoxy-3′-thiacytidine, and 2′,3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J Biol Chem 1994; 269:28118-28122.
34. White KL, Chen JM, Feng JY, Margot NA, Ly JK, Ray AS, et al. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antir Ther 2006; 11:155-163.
35. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191- 201.
36. Grant PM, Taylor J, Nevins AB, Calvez V, Marcelin AG, Wirden M, Zolopa AR. International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of K65R mutation in reverse transcriptase. Antimicrob Agents Chemother 2010; 54:1520-1525.
37. Castagna A, Danise A, Menoz S, Galli L, Gianotti N, Carini E, et al. Lamivudine monotherapy in HIV-1 infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 2006; 20:785-803.
38. van Zyl GU, van der Merwe L, Classen M, Zeier M, Preiser W. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. J Med Virol 2011; 83:1764-1769.
39. Margot NA, Waters JM, Miller MD. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob Agents Chemother 2006; 50:4087-4095.
40. Wainberg MA, Turner D. Resistance issues with new nucleoside/ nucleotide backbone options. J Acquir Immune Defic Syndr 2004; 37:S36-S43.
41. Valer L, Martin-Carbonero L, de Mendoza C, Corral A, Soriano V. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations. AIDS 2004; 18:2094-2096.
42. Parikh UM, Barnas DC, Faruki H, Mellors JW. Antagonism between the HIV-1 reverse transcriptase mutation K65R and thymidine analogue mutations at the genomic level. J Infect Dis 2006; 194:651-660.
43. Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disproxil fumarate treatment in antiretroviral- experienced patients. J Infect Dis 2004; 189:837-846.
44. De Luca, Di Giambenedetto S, Romano L, Gonnelli A, Corsi P, Baldari M, et al. Frequency and treatment related predictors of thymidine analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy. J Infect Dis 2006; 193:1219-1222.
45. Cozzi-Lepri A, Phillips A, Martinez-Picado J, d'Arminio Monforte A, Katlama C, Hansen A, et al. for the EuroSIDA Study Group. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis 2009; 200:687-697.
46. Lyagoba F, Dunn DT, Pillay D, Kityo C, Robertson V, Tugume S, et al. DART Virology and Trial Team. Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring. J Acquir Immune Defic Syndr 2010; 55:277-283.
47. Ndembi N, Goodall RL, Dunn DT, McCormick A, Burke A, Lyagoba F, et al. Development of Antiretroviral Treatment in Africa Virology Group and Trial Team. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudinelamivudine plus Abacavir. J Infect Dis 2010; 201:106- 113.
48. Doualla-Bell F, Gaolathe T, Avalos A, Cloutier S, Ndwapi N, Holcroft C, et al. Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens. J Int AIDS Soc 2009; 12:25.
49. Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, et al. Study Team. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir R saquinavir/ritonavir) regimen in HIVinfected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. HIV Med 2007; 8:529- 535.
50. Rodrguez M, O'Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS 2008; 22:1305- 1312.
51. Laurent C, Bourgeois A, Mpoudi-Ngolé E, Ciaffi L, Kouanfack C, Mougnutou R, et al. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon. AIDS Res Hum Retroviruses 2008; 24:393-399.
52. Hawkins C, Achenbach C, Fryda W, Ngare D, Murphy R. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr 2007; 45:304-310.
53. Shepherd J, Habib A, Charurat M, Mondal P, Falajayo K, Abimiku A, et al. ACTION Project Study Group. Efficacy and tolerability of alternative first-line antiretroviral drug regimens in Nigeria. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia.
54. Snoeck J, Kantor R, Shafer RW, Vandamme AM. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother 2006; 50:694-701.